Repair+ Bundle

Three vials: the Wolverine blend (BPC-157 and TB-500 in one vial), KPV and GHK-Cu, spanning animal tissue-repair research, inflammation research and skin and wound research. It holds the same four peptides at the same amounts as the single-vial KLOW blend, split across three vials. It is not the Wolverine Bundle, which is three separate vials including ipamorelin.

BPC-157 and TB-500 are studied in animals for soft-tissue and wound repair, and FDA found no human studies of TB-500 itself. KPV reduced colitis in mice, mainly given by mouth or in colon-targeted particles, and GHK-Cu's human data are small, mostly industry-linked topical skin studies; whether other routes reproduce either is unknown. No study has tested these four together or any pair, and TB-500 and KPV have no human data at all.

All four carry a theoretical cancer-related concern from animal or cell data, including a mouse finding that KPV's transporter promoted colitis-linked tumors. BPC-157 raised liver enzymes and shifted clotting tests in short animal studies, and clinicians report raised liver enzymes and copper levels in some people who used GHK-Cu outside studies; the 50 mg GHK-Cu vial contains roughly 8 mg of copper. FDA flags immunogenicity or poor characterization for all four, and its review includes recurring skin and gum darkening from a BPC-157/TB-500 blend.

None is an approved drug. BPC-157, TB-500 and KPV left FDA's Category 2 list in April 2026 and received favorable advisory votes (8–6–1 each) in July 2026, but FDA had issued no final rule as of October 2026, so none is compoundable; injectable GHK-Cu has no compounding pathway, though topical GHK-Cu is sold legally in cosmetics. BPC-157 and TB-500 are prohibited at all times by WADA, KPV likely falls under S0, and GHK-Cu is a gray area.